ZFP101 Inhibitors
Chemical inhibitors of the protein ZFP101 can influence its function by various mechanisms, targeting different pathways that are crucial for its regulatory role in gene expression. Chelerythrine, for instance, exerts its effect by inhibiting protein kinase C (PKC), a key player in the phosphorylation and subsequent activation of transcription factors. By impeding PKC, the activation states and functionality of ZFP101 can be directly affected. Similarly, LY294002 and Wortmannin, both phosphoinositide 3-kinases (PI3K) inhibitors, can hamper the PI3K pathway, which is involved in regulating Akt phosphorylation. The inhibition of Akt activity can lead to a decrease in the regulatory influence of ZFP101 on transcriptional mechanisms.
Further down the signaling cascade, PD 98059 and U0126, which are selective inhibitors of MAP kinase kinase (MEK), can prevent the activation of the extracellular signal-regulated kinase (ERK) pathway. Since ERK can modulate the activities of various transcription factors, the inhibition by these chemicals can result in a reduced capacity of ZFP101 to influence gene expression. SP600125 and SB203580, which are inhibitors of c-Jun N-terminal kinase (JNK) and p38 MAP kinase respectively, can disrupt other signaling pathways that are essential for the proper functioning of ZFP101. By inhibiting these kinases, the activation of ZFP101, which may rely on such pathways for its role in stress response and other gene regulatory processes, can be significantly diminished. Additionally, Rapamycin, by inhibiting mTOR, can affect signaling pathways that regulate the stability and activity of transcription factors such as ZFP101. Conversely, Y-27632 targets the Rho-associated protein kinase (ROCK), which is involved in cytoskeletal organization that can influence transcription factor activities, thereby possibly affecting ZFP101 function. Lastly, Thapsigargin and BAPTA-AM can alter intracellular calcium levels, which are critical for the function of calcium-dependent signaling pathways, thus indirectly influencing the activity of ZFP101.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. Inhibition of p38 MAP kinase can prevent activation of transcription factors that are regulated by this pathway, potentially inhibiting the function of ZFP101 in stress response gene expression. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a potent inhibitor of protein kinase C (PKC), a pathway that ZFP101 can be involved in regulating gene expression. The inhibition of PKC can lead to reduced activity of transcription factors including ZFP101 by impeding their phosphorylation and activation states. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MAP kinase kinase (MEK), which can inhibit the ERK pathway. As ZFP101 activity is regulated through phosphorylation by kinases downstream of MEK, inhibition of ERK activation can reduce ZFP101 function in cellular signaling and gene regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. By inhibiting PI3K, this chemical can reduce Akt phosphorylation and activity. As Akt can regulate the function of various transcription factors, this could inhibit ZFP101's role in transcriptional regulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can regulate transcription factor activity. Inhibition of JNK may disrupt signaling pathways that activate ZFP101, leading to a decrease in ZFP101-mediated transcriptional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By inhibiting PI3K activity, Wortmannin can attenuate the phosphorylation and activation of downstream targets that may include transcription factors or coactivators necessary for ZFP101's function in gene regulatory networks. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, Rapamycin can disrupt signaling pathways involved in cell growth and proliferation, which could include pathways that regulate the activity or stability of transcription factors like ZFP101. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2. This MEK inhibition prevents ERK phosphorylation and activation. Since ERK can modulate transcription factor activities, U0126 can inhibit the signaling pathways necessary for ZFP101's transcriptional regulatory functions. | ||||||
LFM-A13 | 62004-35-7 | sc-203623 sc-203623A | 10 mg 50 mg | $119.00 $670.00 | ||
LFM-A13 is a selective inhibitor of Bruton's tyrosine kinase (BTK). BTK is part of signaling pathways that can influence the activity of multiple transcription factors. Inhibition of BTK may therefore impair ZFP101's capacity to regulate gene expression associated with BTK signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK). ROCK is involved in regulating transcription factors through cytoskeletal organization. Inhibition of ROCK may disrupt cellular functions necessary for ZFP101 to exert control over gene expression. | ||||||